Pediatrics

Developed Formulas
Benefits
  • Reduces mucosal inflammation
  • Helps restore intestinal barrier function
  • Counteracts gut dysbiosis
  • Reduces prevalence and duration of antibiotic-associated diarrhea
Pediatrics
Microbac
Pediatrics
In vitro test
Pediatrics
Hydrosoluble powder
Pediatrics
Allergen Free
Pediatrics
Real time stability
Pediatrics
Strain in oil
Components

Limosilactobacillus reuteri LRE02 (DSM 23878)
Lacticaseibacillus rhamnosus LR04 (DSM 16605)

Label Claim

Food supplement with probiotic strains.

Effective nutraceutical combination

Vitamin D
EFSA Claim: contributes to the normal function of the immune system; has a role in the process of cell division
Biotin
EFSA Claim: contributes to the mantainance of normal skin and mucosa

Scientific Rationale

FLOR-EN® Baby is an allergen-free, clean-label formulation specifically designed for infants and children. Presented in an oil suspension, it targets infant dysbiosis and antibiotic-associated diarrhea. The formulation includes two probiotic strains, Limosilactobacillus reuteri LRE02 and Lacticaseibacillus rhamnosus LR04, which are effective in:

  • Preventing damage to gut epithelium integrity and restoring the membrane after damage [1].

  • Modulating the immune response against pathogens by significantly increasing natural killer cell activity [2].

  • Directly inhibiting various pathogenic microorganisms, including multiple strains of pathogenic E. coli, as well as Enterococcus faecalis, Klebsiella pneumoniae, E. coli, and Staphylococcus aureus, attributed to genes coding for bacteriocins [3,4].

In a clinical study, daily supplementation with 5 drops of FLOR-EN® Baby for 30 days in children undergoing treatment with penicillins, cephalosporins, and macrolides significantly reduced the prevalence of antibiotic-associated diarrhea. It also improved stool consistency and decreased the number of days with diarrhea. Notably, there were significant differences in the prevalence of antibiotic-associated diarrhea among the three antibiotic categories between the two groups (p<0.0001) [5].

Bibliography

1. Internal Probiotical data

2. Chamignon C, et al. Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains. Microorganisms. 2020 Jul 15;8(7):1053  doi: 10.3390/microorganisms8071053.

3. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7

4. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.  DOI: 10.35248/2329-8901.20.8.216

5. Drago L, et al. Effect of LimosiLactobacillus reuteri LRE02-Lacticaseibacillus rhamnosus LR04 Combination on Antibiotic- Associated Diarrhea in a Pediatric Population: A National Survey. J Clin Med. 2020 Sep 24;9(10):E3080. DOI: 10.3390/jcm9103080

Associations